Karyopharm Therapeutics Inc.
THE COMBINATION OF XPO1 INHIBITORS AND SECOND AGENTS FOR THE TREATMENT OF PROSTATE CANCER
Last updated:
Abstract:
This invention relates to a method of treating prostate cancer comprising administering a compound of Formula (I) or a salt thereof in combination with either abiraterone or enzalutamide. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
5 Sep 2019
Issue date:
14 Oct 2021